Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis

被引：0
|
作者：
Koike, Tomoyuki
Iijima, Katsunori
Imatani, Akira
Shimosegawa, Tooru
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1117
引用
收藏
页码：S655 / S655
页数：1
相关论文
共 50 条
  • [21] Effect of lansoprazole and rabeprazole on intragastric,acidity in relation to CYP2C19 genotype status.
    Sukegawa, M
    Hokari, K
    Takeda, H
    Sugiyama, T
    Kato, M
    Asaka, M
    GASTROENTEROLOGY, 2000, 118 (04) : A1310 - A1310
  • [22] Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy
    Kuo, Chao-Hung
    Wang, Sophie S. W.
    Hsu, Wen-Hung
    Kuo, Fu-Chen
    Weng, Bi-Chuang
    Li, Chia-Jung
    Hsu, Ping-I
    Chen, Angela
    Hung, Wen-Chun
    Yang, Yuan-Chieh
    Wang, Wen-Ming
    Wu, Deng-Chyang
    HELICOBACTER, 2010, 15 (04) : 265 - 272
  • [23] Effect of CYP2C19 polymorphism on rabeprazole induced nocturnal acid breakthrough
    Park, SH
    Kim, JW
    Lee, SY
    Choi, MG
    Kim, JK
    Choi, KY
    Chung, IS
    Sun, HS
    Park, DH
    GASTROENTEROLOGY, 2001, 120 (05) : A435 - A435
  • [24] CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
    Tsung-Jung Lin
    Hsi-Chang Lee
    Chih-Lin Lin
    Chung-Kwe Wang
    Kuan-Yang Chen
    Deng-Chyang Wu
    World Journal of Clinical Cases, 2018, 6 (12) : 514 - 520
  • [25] CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
    Lin, Tsung-Jung
    Lee, Hsi-Chang
    Lin, Chih-Lin
    Wang, Chung-Kwe
    Chen, Kuan-Yang
    Wu, Deng-Chyang
    WORLD JOURNAL OF CLINICAL CASES, 2018, 6 (12) : 514 - 520
  • [26] CYP2C19 genotype and the PPIs - focus on rabeprazole
    Lim, PWY
    Goh, KL
    Wong, BCY
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S22 - S28
  • [27] Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism
    Takahashi, K
    Motohashi, H
    Yonezawa, A
    Okuda, M
    Ito, N
    Yamamoto, S
    Ogawa, O
    Inui, K
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 791 - 794
  • [28] Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Hishida, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 361 - 361
  • [29] Lansoprazole + clarithromycin: interaction independent of CYP2C19
    Reactions Weekly, 2005, 1052 (1) : 3 - 3
  • [30] The CYP2C19 enzyme polymorphism
    Wedlund, PJ
    PHARMACOLOGY, 2000, 61 (03) : 174 - 183
12345